Mydecine Innovations Group ( (TSE:MYCO) ) has shared an update.
Mydecine Innovations Group has announced significant changes to its board and management team. Peter Field, an experienced entrepreneur with a background in business development and biotech, has joined the board of directors. Additionally, Michael Callas, a tech industry leader and founder of EVOOAI, has been appointed to the board following the resignation of Robert Roscow. The company also announced the resignation of Damon Michaels as Chief Operating Officer. These changes are expected to bring fresh perspectives and expertise to Mydecine, potentially impacting its strategic direction and operations in the biotechnology sector.
More about Mydecine Innovations Group
Mydecine Innovations Group is a biotechnology company focused on developing innovative medications and therapies for mental health disorders, including nicotine addiction and PTSD. The company combines advanced technology with a robust infrastructure for drug discovery and development, aiming to create breakthrough treatment solutions in areas with significant unmet needs. Mydecine is dedicated to advancing the next generation of psychedelic medicine through clinical trials and collaborations with leading specialists.
Average Trading Volume: 46,705
Technical Sentiment Signal: Buy
Current Market Cap: C$308.8K
See more data about MYCO stock on TipRanks’ Stock Analysis page.